Mechanisms of dysfunction of the nitric oxide pathway in vascular diseases

Nitric Oxide - Biology and Chemistry

Volumn 6, Issue 2, 2002, Pages 101-124

  Maxwell, Andrew J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Asymmetric dimethylarginine; Atherosclerosis; Endothelium; L arginine; Nitric oxide synthase; Oxidative stress; Superoxide

Indexed keywords

ARGININE; NITRIC OXIDE SYNTHASE; SUPEROXIDE;

ATHEROSCLEROSIS; CELL COMPARTMENTALIZATION; DUCHENNE MUSCULAR DYSTROPHY; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MICROCIRCULATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVIEW; VASCULAR DISEASE;

EID: 0036331059     PISSN: 10898603     EISSN: None     Source Type: Journal    
DOI: 10.1006/niox.2001.0394     Document Type: Review

References (167)

1. alpha1-syntrophin gene disruption results in the absence of neuronal-type nitric-oxide synthase at the sarcolemma but does not induce muscle degeneration
2. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy
3. Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle
4. Effects of ingestion of disproportionate amounts of amino acids
5. Characterization of L-arginine uptake by plasma membrane vesicles isolated from cultured pulmonary artery endothelial cells
6. Characterization of L-arginine transport by pulmonary artery endothelial cells
7. Voltage dependence of facilitated arginine flux mediated by the system y+ basic amino acid transporter
8. Cell-surface receptor for ecotropic murine retroviruses is a basic amino-acid transporter
9. Diabetes-induced activation of system y+ and nitric oxide synthase in human endothelial cells: Association with membrane hyperpolarization
10. Nitric oxide synthase: Expression and expressional control of the three isoforms
11. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide sythase gene expression
12. Palmitoylation of endothelial nitric oxide synthase is necessary for optimal stimulated release of nitric oxide: Implications for caveolae localization
13. A chimeric transmembrane domain directs endothelial nitric-oxide synthase palmitoylation and targeting to plasmalemmal caveolae
14. Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: Implications for nitric oxide signaling
15. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions
16. Characterization of bovine endothelial nitric oxide synthase as a homodimer with down-regulated uncoupled NADPH oxidase activity: Tetrahydrobiopterin binding kinetics and role of haem in dimerization
17. Biosynthesis of tetrahydrobiopterin in the presence of dihydrofolate reductase inhibitors
18. Biosynthesis of tetrahydrobiopterin by de novo and salvage pathways in adrenal medulla extracts, mammalian cell cultures, and rat brain in vivo
19. Tetrahydrobiopterin synthesis. An absolute requirement for cytokine-induced nitric oxide generation by vascular smooth muscle
20. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt
21. The Akt kinase signals directly to endothelial nitric oxide synthase
22. Mechanical transduction in biologic systems
23. Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator
24. 2+-permeable channel
25. Phosphorylation and activation of the endothelial nitric oxide synthase by fluid shear stress
26. Cyclic nucleotide dependent relaxation in vascular smooth muscle
27. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation
28. Enhanced electron flux and reduced calmodulin dissociation may explain "calcium-independent" eNOS activation by phosphorylation
29. Dynamin-2 binds and directly activates endothelial nitric oxide synthase
30. Dynamic activation of endothelial nitric oxide synthase by Hsp90
31. Hsp90 regulation of endothelial nitric oxide synthase contributes to vascular control in portal hypertension
32. Reconstitution of an endothelial nitric oxide synthase, hsp90 and caveolin-1 complex in vitro: Evidence that hsp90 facilitates calmodulin stimulated displacement of eNOS from caveolin-1
33. Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin-1
34. Nitric oxide reversibly suppresses xanthine oxidase activity
35. Regulation of xanthine oxidase by nitric oxide and peroxynitrite
36. Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B
37. Inactivation of zinc finger transcription factors provides a mechanism for a gene regulatory role of nitric oxide
38. Xanthine oxidoreductase catalyses the reduction of nitrates and nitrite to nitric oxide under hypoxic conditions
39. Reduction of organic nitrites to nitric oxide catalyzed by xanthine oxidase: Possible role in metabolism of nitrovasodilators
40. The discovery of nitric oxide as the endogenous nitrovasodilator
41. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells
42. Control of regional blood flow by endothelium-derived nitric oxide
43. Inhibition of synthesis of endothelium-derived nitric oxide in conscious dogs-hemodynamic, renal and hormonal effects
44. Effects of oral administration of L-arginine on hemodynamics and exercise capacity in patients with pulmonary hypertension
45. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P
46. Nitric oxide promotes proliferation and plasminogen activator production by coronary venular endothelium through endogenous bFGF
47. Role of endothelial nitric oxide synthase in endothelial cell migration
48. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling
49. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia
50. Nitric oxide-generating vasodilators inhibit mitogenesis and proliferation of BALB/C 3T3 fibroblasts by a cyclic GMP-independent mechanism
51. Nitric oxide decreases cytokine-induced endothelial activation
52. Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide
53. S-nitrosylation of proteins with nitric oxide: Synthesis and characterization of biologically active compounds
54. Inhibition of low-density lipoprotein oxidation by nitric oxide. Potential role in atherogenesis
55. Nitric oxide, an endothelial cell relation factor, inhibits neutrophil superoxide anion production via a direct action ofn NADPH oxidase
56. Fluid flow inhibits endothelial adhesiveness. Nitric oxide and transcriptional regulation of VCAM-1
57. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells
58. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis
59. Cellular and molecular studies of atherogenesis
60. Exposure to shear stress alters endothelial adhesiveness: Role of nitric oxide
61. Nitric oxide regulates monocyte chemotactic protein-1
62. Nitric oxide-generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells
63. The anti-aggregating properties of vascular endothelium: Interactions between prostacyclin and nitric oxide
64. Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans
65. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium
66. Identification of constitutive and inducible forms of nitric oxide synthase in human platelets
67. Impaired endothelium-dependent vasodilation of large epicardial and resistance coronary arteries in patients with essential hypertension. Different responses to acetylcholine and substance P
68. Coronary vascular nitric oxide activity in hypertension and hypercholesterolemia. Comparison of acetylcholine and substance P
69. Impaired endothelium-dependent vasodilation in patients with essential hypertension: Evidence that the abnormality is not at the muscarinic receptor level
70. Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway
71. Selective defect in nitric oxide synthesis may explain the impaired endothelium-dependent vasodilation in patients with essential hypertension
72. Interactions between L-arginine and L-glutamine change endothelial NO production. An effect independent of NO synthase substrate availability
73. Non-invasive detection of endothelial dysfunction in patients with essential hypertension
74. Loss of flow-dependent coronary artery dilatation in patients with hypertension
75. Dietary protein or arginine deficiency impairs constitutive and inducible nitric oxide synthesis by young rats
76. Arginine "Requirement" for individuals at risk for atherosclerosis
77. Role of arginine in health and in renal disease
78. Arginine: New and exciting developments for an "old" amino acid
79. Cardiovascular effects of L-arginine
80. Positive and negative outcomes of L-arginine therapy in cardiovascular diseases
81. L-arginine-Its role in cardiovascular therapy
82. A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the "arginine paradox"
83. Role of membrane potential in hypoxic inhibition of L-arginine uptake by lung endothelial cells
84. Activation of A2-purinoceptors by adenosine stimulates L-arginine transport (system y+) and nitric oxide synthesis in human fetal endothelial cells
85. Dysfunction of the endothelial nitric oxide signalling pathway in diabetes and hyperglycaemia
86. Endotoxin-induced nitric oxide production in pulmonary artery endothelial cells is regulated by cytokines
87. Cytokines regulate endotoxin stimulation of endothelial cell arginine transport
88. Endotoxin stimulates arginine transport in pulmonary artery endothelial cells
89. Activation of L-arginine transport (system y+) and nitric oxide synthase by elevated glucose and insulin in human endothelial cells
90. Oxidized LDL decreases L-arginine uptake and nitric oxide synthase protein expression in human platelets: Relevance of the effect of oxidized LDL on platelet function
91. Effects of interferon gamma on arginase II mRNA and protein stability in lipopolysaccharide treated rat aortic smooth muscle cells
92. Co-induction of arginase and nitric oxide synthase in murine macrophages activated by lipopolysaccharide
93. IL-4 and IL-13 upregulate arginase I expression by cyclic AMP and possible JAK?STAT6 pathways in vascular smooth muscle cells
94. Blood serum arginase activity in right and left-ventricular failure
95. Increased L-arginine transport in human erythrocytes in chronic heart failure
96. Nitrogen metabolism in sickle cell anemia: Free amino acids in plasma and urine
97. Serum and urinary amino acid levels in sickle cell disease
98. Early diagnosis of myocardial infarction by arginase activity determination
99. Evidence that L-arginine is a key amino acid in sickle cell anemia
100. Sickle reticulocytes adhere to VCAM-1
101. Inhibition of nitric oxide synthesis by cigarette smoke
102. The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: L-Glutamine inhibits the generation of L-arginine by cultured endothelial cells
103. The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: Cultured endothelial cells recycle L-citrulline to L-arginine
104. L-glutamine inhibits the release of endothelium-derived relaxing factor from the rabbit aorta
105. Regulation processes in biological systems. II. Role of compartmentation and of organized multienzyme systems
106. Temporal analysis of metabolic systems and its application to metabolite channelling
107. Nitric oxide synthase I (NOS-I) is deficient in the sarcolemma of striated muscle fibers in patients with Duchenne muscular dystrophy, suggesting an association with dystrophin
108. Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation
109. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion
110. L-Arginine treatment alters the kinetics of nitric oxide and superoxide release and reduces ischemia/reperfusion injury in skeletal muscle
111. Comparative functioning of dihydro- and tetrahydropterins in supporting electron transfer, catalysis, and subunit dimerization in inducible nitric oxide synthase
112. N-terminal domain swapping and metal ion binding in nitric oxide synthase dimerization
113. Subunit dissociation and reassociation of nitric oxide synthases: Comparitive analysis of the role of arginine and tetrahydrobiopterin among the three isoforms
114. Tetrahydrobioterin (BH4)/dihydrobiopterin (BH2) ratio but not ascorbate controls the release of superoxide and nitric oxide from nitric oxide synthase
115. Tetrahydrobiopterin and dysfunction of endothelial nitric oxide synthase in coronary arteries
116. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia
117. Smoking impairs the activity of endothelial nitric oxide synthase in saphenous vein
118. L-ascorbic acid potentiates endotheliual nitric oxide synthesis by increasing intracellular tetrahydrobiopterin levels
119. Effects of cyclosporin A and FK506 on nitric oxide and tetrahydrobiopterin synthesis in bacterial lipopolysaccharide-treated J774 macrophages
120. Superoxide and peroxynitrite in atherosclerosis
121. Physiologic consequences of increased vascular oxidant stresses in hypercholesterolemia and atherosclerosis: Implications for impaired vasomotion
122. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis
123. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase
124. Asymmetric dimethylarginine: A new risk factor for endothelial dysfunction
125. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease
126. Endogenous nitric oxide synthase inhibitor: A novel marker of atherosclerosis
127. Smoking is associated with increased plasma asymmetric dimethylarginine (ADMA) levels in patients with type 2 diabetes mellitus
128. Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension
129. Elevated plasma level of asymmetric dimethylarginine (ADMA) is associated with coronary artery disease independent of the traditional atherosclerotic risk factors
130. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure
131. Structural specificity of substrate for S-adenosylmethionine, protein arginine N-methyltransferases
132. Occurrence of a new enzyme catalyzing the direct conversion of NG,NG-dimethyl-L-arginine to L-citrulline in rats
133. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases
134. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase
135. Novel mechanism for endothelial dysfunction: Dysregulation of dimethylarginine dimethylaminohydrolase
136. Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with myocardial infarction
137. Endothelial nitric oxide synthase gene is positively associated with essential hypertension
138. Glu298Asp polymorphism of endothelial nitric oxide synthase in essential hypertension resistant to conventional therapy
139. A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese
140. A common variant of the endothelial nitric oxide synthase (Glu298->Asp) is a major risk factor for coronary artery disease in the UK
141. Endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction
142. Regulation of expression of the endothelial cell nitric oxide synthase
143. Characterization of the human endothelial nitric-oxide synthase promoter
144. Expressional control of the endothelial NO synthase
145. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
146. Protein interations with the 3′-untranslated region of mRNA regulates endothelial nitric oxide synthase mRNA stability
147. Effects of two calcium channel blockers on messenger RNA expression of endothelin-1 and nitric oxide synthase in cardiovascular tissue of hypertensive rats
148. The physiology and pathophysiology of the nitric oxide/superoxide system
149. Activation of NADPH oxidase required for macrophage-mediated oxidation of low-density lipoprotein
150. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine
151. Homocysteine-induced inhibition of endothelium-dependent relaxation in rabbit aorta: Role for superoxide anions
152. Homocysteine induces accumulation of ADMA, Role of DDAH and antioxidants
153. Homocysteine prevents NO-mediated induction of heme oxygenase-1 in vascular endothelial cells
154. Homocysteine theory of arteriosclerosis
155. Role of superoxide anions in changes of endothelial vasoactive response during acute hyperglycemia
156. Peroxidative stress in diabetic blood vessels. Reversal by pancreatic islet transplantation
157. Free radicals mediate endothelial cell dysfunction caused by elevated glucose
158. Advanced glycation end-products and atherosclerosis
159. Toxic action of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: Relevance to diabetic retinopathy
160. RAGE: A novel cellular receptor for advanced glycation end products
161. Expressional regulation of soluble guanylyl cyclase
162. The effect of aging and hyperglycemia on NO mediated action in rat aorta - The relation of eNOS and soluble guanylate cylase activity
163. Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats
164. Effect of some cyclooxygenase inhibitors on the increase in guanosine 3′:5′-cyclic monophosphate induced by NO-donors in human whole platelets
165. Aspirin activates intracellular cyclic GMP synthesis via NO-dependent pathways
166. Increased nitrovasodilator sensitivity in endothelial nitric oxide synthase knockout mice: Role of soluble guanylyl cyclase
167. Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ domains